https://www.selleckchem.com/pr....oducts/Gefitinib.htm
Epidermal growth factor receptor (EGFR) exon 20 insertion ( ex20ins) is a common mutation in non-small cell lung cancer (NSCLC). Patients with ex20ins generally respond poor to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). ex20ins are often co-occurring with amplification. However, the impact of amplification on the survival of patients with ex20ins mutations has not been determined. This is an observational longitudinal cohort study. A prospectively managed database included consecutive treatment-naïve adult patients with advanced NSC
Like
Comment
Share
